Having trouble accessing articles? Reset your cache.

REGN88: Phase I data

In a Phase I trial in 107 patients, single subcutaneous injections of REGN88 dose-dependently

Read the full 143 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE